China’s CanSinoBIO H1 revenue drops on weaker COVID shot demand
BEIJING (Reuters) – China’s CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic …
cansinobio
BEIJING (Reuters) – China’s CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic …